Core Viewpoint - The avian influenza concept sector has seen a significant increase, with a rise of 2.45%, ranking third among concept sectors on the trading day ending August 19. Group 1: Sector Performance - The avian influenza sector had 18 stocks rising, with ST Xiangxue hitting a 20% limit up, and Kangyuan Pharmaceutical also reaching the limit up. Other notable gainers included Yongshun Biological, Lianhuan Pharmaceutical, and Zhongsheng Pharmaceutical, which rose by 9.35%, 6.08%, and 3.79% respectively [1] - The top-performing concept sectors included: - Reducer: +2.62% - Animal Vaccine: +2.47% - Avian Influenza: +2.45% [1] Group 2: Capital Flow - The avian influenza sector attracted a net inflow of 109 million yuan, with 15 stocks receiving net inflows. Five stocks had net inflows exceeding 10 million yuan, led by Kangyuan Pharmaceutical with a net inflow of 154 million yuan [1] - The top stocks by net capital inflow ratio included: - Kangyuan Pharmaceutical: 19.87% - ST Xiangxue: 14.18% - Zhongmu Stock: 5.23% [2]

Core Viewpoint - ZSP1601 is an innovative drug targeting metabolic dysfunction-related fatty liver disease (MASH) and is currently in the IIb phase of clinical trials [2] Company Summary - Zhongsheng Pharmaceutical (002317.SZ) confirmed that ZSP1601 is a novel drug with a new mechanism of action [2] - The drug is part of a major national new drug creation project [2]

Core Viewpoint - On August 19, Zhongsheng Pharmaceutical experienced an intraday increase of 8.36%, reaching a stock price of 24.88 yuan per share, with a trading volume of 1.238 billion yuan and a turnover rate of 6.81%, resulting in a total market capitalization of 21.146 billion yuan [1] Company Overview - Guangdong Zhongsheng Pharmaceutical Co., Ltd. is located in Dongguan City, Guangdong Province, and is a top 100 pharmaceutical company focusing on ophthalmology, cardiovascular, respiratory, and digestive treatment areas [1] - The company operates ten subsidiaries and four production bases, with major products including Compound Thrombus Capsule, Brain Thrombus Capsule, and Zhongsheng Pill [1] - Zhongsheng Pharmaceutical has 16 chemical drug products that have passed the consistency evaluation of generic drugs, with five products selected in the national centralized procurement [1] - The company has established a multi-level R&D system based on characteristic traditional Chinese medicine, high-end generic drugs, and innovative drugs, with the innovative drug Liratevir Tablets approved for market on March 23, 2023 [1] Financial Performance - For the period from January to March 2025, Zhongsheng Pharmaceutical achieved an operating income of 634 million yuan, a year-on-year decrease of 1.07%, while the net profit attributable to shareholders was 82.6118 million yuan, reflecting a year-on-year increase of 61.06% [1] - As of March 31, the number of shareholders of Zhongsheng Pharmaceutical was 91,100, with an average of 8,359 circulating shares per person [1]

Group 1 - The latest stock price of Zhongsheng Pharmaceutical is 22.96 yuan, up 1.91% from the previous trading day, with an intraday high of 23.54 yuan and a low of 22.38 yuan, and a total trading volume of 1.633 billion yuan [1] - The company’s main business includes the research, production, and sales of traditional Chinese medicine, chemical drugs, raw materials, and health products, covering multiple therapeutic areas such as cardiovascular, respiratory, and digestive systems [1] - Zhongsheng Pharmaceutical's third extraordinary general meeting of shareholders in 2025 approved the proposal regarding the redemption of part of the equity of its controlling subsidiary and related transactions, indicating an adjustment in the company's equity structure [1] Group 2 - Data on capital flow shows a net inflow of 41.5428 million yuan from main funds on that day, accounting for 0.24% of the circulating market value, while the cumulative net outflow over the past five trading days reached 96.9596 million yuan, representing 0.55% of the circulating market value [1]

（文章来源：证券日报） 证券日报网讯 8月18日晚间，众生药业发布公告称，公司2025年第三次临时股东大会于2025年8月18日 召开，审议通过了《关于赎回控股子公司部分股权暨关联交易的议案》。 ...

股东大会法律意见书 北京海润天睿律师事务所 关于广东众生药业股份有限公司 2025 年第三次临时股东大会的法律意见书 中国·北京 北京市朝阳区建外大街甲 14 号广播大厦 5 层&9 层&10 层&13 层&17 层 电话（Tel）：86-10-65219696 传真（Fax）：86-10-88381869 股东大会法律意见书 北京海润天睿律师事务所 关于广东众生药业股份有限公司 2025 年第三次临时股东大会的法律意见书 致：广东众生药业股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受广东众生药业股份有限 公司（以下简称"公司"）的委托，指派冯玫律师、王佩琳律师出席公司 2025 年第三次临时股东大会，并依据《中华人民共和国证券法》（以下简称"《证券 法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、《广东众 生药业股份有限公司章程》（以下简称"《公司章程》")及其他相关法律、法 规和规范性文件的规定，就公司本次股东大会的召集、召开程序、出席会议人员 的资格、召集人资格、表决程序、表决结果等有关事宜出具本法律意见书。 4．本法律意见书仅供公司本次会议之目的使用，不得用作任何其他用途。 ...

证券代码：002317 公告编号：2025-087 广东众生药业股份有限公司 2、本次临时股东大会不存在否决提案，无涉及变更前次股东大会决议的情 形。 一、会议召开和出席情况 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次临时股东大会以现场投票和网络投票相结合的方式召开。 广东众生药业股份有限公司（以下简称"公司"）2025 年第三次临时股东大 会采取现场投票与网络投票相结合的方式召开。 （一）会议召开的时间： 1、现场会议召开时间：2025 年 8 月 18 日下午 2:45 2、网络投票时间： （1）通过深交所交易系统进行网络投票的具体时间为 2025 年 8 月 18 日 9:15～9:25，9:30～11:30 和 13:00～15:00； （2）通过互联网投票系统投票的具体时间为 2025 年 8 月 18 日 9:15～15:00。 （二）现场会议召开地点：公司会议室 （三）会议召集人：公司董事会 （四）现场会议主持人：公司董事长陈永红先生 （五）会议出席情况： （六）本次会议符合有关法 ...

Group 1 - The core viewpoint of the news is that the A-share market saw a collective rise in weight-loss drug concept stocks, driven by the accelerated approval of Wegovy by the FDA for treating certain liver conditions [1][2]. - Han Yu Pharmaceutical (300199) experienced a significant increase of over 14%, while other companies like Jin Kai Biotechnology and Shengnuo Bio rose by over 12% and 6% respectively [1][2]. - Novo Nordisk's stock rose over 6% in after-hours trading following the FDA's announcement regarding Wegovy [1]. Group 2 - The following companies showed notable stock performance: - Han Yu Pharmaceutical (300199) with a rise of 14.66% and a total market value of 26.4 billion [2]. - Jin Kai Biotechnology (301509) increased by 12.28% with a market value of 5.1 billion [2]. - Shengnuo Bio (688117) rose by 6.00% and has a market value of 7.229 billion [2]. - Yangguang Nuohuo (688621) increased by 4.37% with a market value of 8.96 billion [2]. - ST Nuotai (688076) rose by 4.08% with a market value of 15 billion [2]. - Other companies like Zhongsheng Pharmaceutical and Kangyuan Pharmaceutical also saw increases close to 4% [1][2].

数据显示，截至2025年7月31日，中证中药指数(930641)前十大权重股分别为云南白药(000538)、片仔癀 (600436)、同仁堂(600085)、东阿阿胶(000423)、华润三九(000999)、白云山(600332)、吉林敖东 (000623)、众生药业(002317)、以岭药业(002603)、佐力药业(300181)，前十大权重股合计占比54.58%。 中药ETF(159647)，场外联接A：016891；联接C：016892；联接I：022881。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 截至2025年8月18日 09:54，中证中药指数(930641)强势上涨1.62%，成分股天士力(600535)上涨8.03%， 新天药业(002873)上涨7.01%，达仁堂(600329)上涨6.07%，众生药业(002317)，康缘药业(600557)等个股 跟涨。中药ETF(159647)上涨1.53%，最新价报1.06元。 东吴证券指出，创新药产业已现拐点：现阶段的中国创新药在政策和研发两端都完成了厚积薄发。政策 端，《全链条支持创新药发展实施方案》在支付端、 ...

Group 1 - The core viewpoint of the news is that the A-share market's weight-loss drug concept stocks have collectively risen due to the accelerated approval of Wegovy by the FDA for treating certain liver conditions [1] - Han Yu Pharmaceutical saw a significant increase of over 14%, while Jin Kai Biotechnology and Sheng Nuo Bio both rose by over 12% and 6% respectively [1] - The approval of Wegovy is expected to positively impact Novo Nordisk, which saw its stock rise over 6% in after-hours trading [1] Group 2 - The following are the stock performance details of key companies in the weight-loss drug sector: - Han Yu Pharmaceutical: 14.66% increase, market cap of 26.4 billion [2] - Jin Kai Biotechnology: 12.28% increase, market cap of 5.1 billion [2] - Sheng Nuo Bio: 6.00% increase, market cap of 7.229 billion [2] - Yang Guang Nuo He: 4.37% increase, market cap of 8.96 billion [2] - ST Nuo Tai: 4.08% increase, market cap of 15 billion [2] - Zhong Sheng Pharmaceutical: 3.99% increase, market cap of 19.9 billion [2] - Kang Yuan Pharmaceutical: 3.97% increase, market cap of 10.4 billion [2]